CH593992A5
(es)
*
|
1972-12-23 |
1977-12-30 |
Roehm Gmbh |
|
GB1550819A
(en)
*
|
1975-06-04 |
1979-08-22 |
Nat Res Dev |
Polymeric support for biogically active materials
|
JPS5272284A
(en)
*
|
1975-12-12 |
1977-06-16 |
Dainippon Pharmaceutical Co |
Enzymeeimmunoassay reagent
|
US4108804A
(en)
*
|
1975-12-23 |
1978-08-22 |
Toru Seita |
Process for preparation of chromatography solid supports comprising a nucleic acid base-epoxy group containing porous gel
|
US4046723A
(en)
*
|
1976-04-22 |
1977-09-06 |
The Dow Chemical Company |
Azide bonding of a protein to a latex
|
US4206261A
(en)
*
|
1976-06-09 |
1980-06-03 |
Schenectady Chemicals, Inc. |
Water-soluble polyester imide resin wire coating process
|
US4179423A
(en)
*
|
1976-06-09 |
1979-12-18 |
Schenectady Chemicals, Inc. |
Water-soluble polyester imide resins
|
US4045384A
(en)
*
|
1976-07-23 |
1977-08-30 |
The Dow Chemical Company |
Method for forming an amide bond between a latex and protein
|
DE2708018A1
(de)
*
|
1977-02-24 |
1978-09-07 |
Boehringer Mannheim Gmbh |
An polyamid fixiertes biologisch aktives protein und verfahren zu seiner herstellung
|
US4275000A
(en)
*
|
1977-08-22 |
1981-06-23 |
National Research Development Corporation |
Peptide macromolecular complexes
|
US4206286A
(en)
*
|
1977-11-14 |
1980-06-03 |
Technicon Instruments Corporation |
Immobilization of proteins on inorganic supports
|
US4338398A
(en)
*
|
1979-03-20 |
1982-07-06 |
Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo |
Immobilization of starch degrading enzymes
|
US4415665A
(en)
*
|
1980-12-12 |
1983-11-15 |
Pharmacia Fine Chemicals Ab |
Method of covalently binding biologically active organic substances to polymeric substances
|
DE3126551C2
(de)
*
|
1981-07-04 |
1983-12-15 |
Rolf Dr. 8700 Würzburg Siegel |
Herstellungsverfahren für Materialien zur Immobilisierung von Proteinen und Kohlenhydratgruppen
|
US4506019A
(en)
*
|
1982-09-24 |
1985-03-19 |
Leeco Diagnostics, Inc. |
Activated polymer container means and assay method employing the same
|
US4596777A
(en)
*
|
1983-08-10 |
1986-06-24 |
E. R. Squibb & Sons, Inc. |
Process for preparing (3S)-3-[[[2-(protected or unprotected amino)-4-thiazolyl]acetyl]amino]-2-oxo-1-azetidinesulfonic acid and 4-substituted derivatives thereof
|
US4752638A
(en)
*
|
1983-11-10 |
1988-06-21 |
Genetic Systems Corporation |
Synthesis and use of polymers containing integral binding-pair members
|
US4609707A
(en)
*
|
1983-11-10 |
1986-09-02 |
Genetic Systems Corporation |
Synthesis of polymers containing integral antibodies
|
DE3486275T2
(de)
*
|
1983-11-10 |
1994-09-08 |
Genetic Systems Corp |
Integralantikörper enthaltende polymerisierbare Verbindungen und deren Anwendungen in Immuntesten mit durch Polymerisation induzierter Trennung.
|
US4711840A
(en)
*
|
1984-01-27 |
1987-12-08 |
Genetic Systems Corporation |
Polymerization-induced separation immunoassays
|
US4511478A
(en)
*
|
1983-11-10 |
1985-04-16 |
Genetic Systems Corporation |
Polymerizable compounds and methods for preparing synthetic polymers that integrally contain polypeptides
|
US4843010A
(en)
*
|
1983-11-10 |
1989-06-27 |
Genetic Systems Corporation |
Polymerization-induced separation immunoassays
|
JPH0820447B2
(ja)
*
|
1984-01-27 |
1996-03-04 |
ジェネティック システムズ コーポレーション |
液体混合物から物質を分離する方法及び免疫評価法
|
US4695624A
(en)
*
|
1984-05-10 |
1987-09-22 |
Merck & Co., Inc. |
Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
|
US4749647A
(en)
*
|
1984-06-22 |
1988-06-07 |
Genetic Systems Corporation |
Polymerization-induced separation assay using recognition pairs
|
DE3784592T2
(de)
*
|
1986-08-07 |
1993-09-23 |
Minnesota Mining & Mfg |
Stabile, biologisch-aktive, fluorchemische emulsionen.
|
US4808530A
(en)
*
|
1986-09-05 |
1989-02-28 |
The Ohio State University |
Protein immobilization by adsorption of a hydrophobic amidine protein derivative to a hydrophobic surface
|
US4885250A
(en)
*
|
1987-03-02 |
1989-12-05 |
E. I. Du Pont De Nemours And Company |
Enzyme immobilization and bioaffinity separations with perfluorocarbon polymer-based supports
|
US5063109A
(en)
*
|
1988-10-11 |
1991-11-05 |
Abbott Laboratories |
Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
ES2084069T3
(es)
*
|
1990-08-15 |
1996-05-01 |
Abbott Lab |
Reactivos de inmunoensayo y metodo para la determinacion de ciclosporina.
|
US5612034A
(en)
*
|
1990-10-03 |
1997-03-18 |
Redcell, Inc. |
Super-globuling for in vivo extended lifetimes
|
US5482996A
(en)
*
|
1993-12-08 |
1996-01-09 |
University Of Pittsburgh |
Protein-containing polymers and a method of synthesis of protein-containing polymers in organic solvents
|
JP3805785B2
(ja)
*
|
1994-01-11 |
2006-08-09 |
ダイアックス コープ. |
カリクレイン阻害クニッツドメイン蛋白質およびその相同体
|
US6057287A
(en)
|
1994-01-11 |
2000-05-02 |
Dyax Corp. |
Kallikrein-binding "Kunitz domain" proteins and analogues thereof
|
US6045797A
(en)
*
|
1994-03-14 |
2000-04-04 |
New York University Medical Center |
Treatment or diagnosis of diseases or conditions associated with a BLM domain
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
US5736624A
(en)
*
|
1994-12-02 |
1998-04-07 |
Abbott Laboratories |
Phosphatase activated crosslinking, conjugating and reducing agents; methods of using such agents; and reagents comprising phosphatase activated crosslinking and conjugating agents
|
US5837815A
(en)
*
|
1994-12-15 |
1998-11-17 |
Sugen, Inc. |
PYK2 related polypeptide products
|
US5837524A
(en)
*
|
1994-12-15 |
1998-11-17 |
Sugen, Inc. |
PYK2 related polynucleotide products
|
US5807989A
(en)
*
|
1994-12-23 |
1998-09-15 |
New York University |
Methods for treatment or diagnosis of diseases or disorders associated with an APB domain
|
US6300482B1
(en)
*
|
1995-01-03 |
2001-10-09 |
Max-Flanck-Gesellschaft Zuer For{Overscore (D)}Erung Der |
MDKI, a novel receptor tyrosine kinase
|
US6565842B1
(en)
*
|
1995-06-07 |
2003-05-20 |
American Bioscience, Inc. |
Crosslinkable polypeptide compositions
|
US7005505B1
(en)
|
1995-08-25 |
2006-02-28 |
Genentech, Inc. |
Variants of vascular endothelial cell growth factor
|
US6020473A
(en)
*
|
1995-08-25 |
2000-02-01 |
Genentech, Inc. |
Nucleic acids encoding variants of vascular endothelial cell growth factor
|
JPH11511328A
(ja)
|
1995-09-15 |
1999-10-05 |
ベイラー・カレッジ・オブ・メディスン |
ステロイドレセプター共活性化因子組成物および使用方法
|
US6030945A
(en)
*
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
US20050089958A1
(en)
*
|
1996-01-09 |
2005-04-28 |
Genentech, Inc. |
Apo-2 ligand
|
US6046048A
(en)
*
|
1996-01-09 |
2000-04-04 |
Genetech, Inc. |
Apo-2 ligand
|
US6998116B1
(en)
*
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
US20020165157A1
(en)
*
|
1996-04-01 |
2002-11-07 |
Genentech, Inc. |
Apo-2LI and Apo-3 polypeptides
|
WO1997037020A1
(en)
|
1996-04-01 |
1997-10-09 |
Genentech, Inc. |
Apo-2li and apo-3 apoptosis polypeptides
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
US6462176B1
(en)
*
|
1996-09-23 |
2002-10-08 |
Genentech, Inc. |
Apo-3 polypeptide
|
US20040241645A1
(en)
*
|
1997-01-31 |
2004-12-02 |
Genentech, Inc. |
O-fucosyltransferase
|
ATE356212T1
(de)
|
1997-01-31 |
2007-03-15 |
Genentech Inc |
O-fukosyltransferase
|
US20020102706A1
(en)
*
|
1997-06-18 |
2002-08-01 |
Genentech, Inc. |
Apo-2DcR
|
US20100152426A1
(en)
*
|
1997-05-15 |
2010-06-17 |
Ashkenazi Avi J |
Apo-2 receptor fusion proteins
|
DE69838249T3
(de)
|
1997-05-15 |
2012-01-19 |
Genentech, Inc. |
Anti-apo-2 antikörper
|
US6342369B1
(en)
*
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
EP1003856A1
(en)
|
1997-06-05 |
2000-05-31 |
Board of Regents, The University of Texas System |
Apaf-1, the ced-4 human homolog, an activator of caspase-3
|
EP1032661A1
(en)
*
|
1997-06-18 |
2000-09-06 |
Genentech, Inc. |
Apo-2DcR
|
AU8569698A
(en)
*
|
1997-07-11 |
1999-02-08 |
Brandeis University |
Method of inducing apoptosis by reducing the level of thiamin
|
CA2301847A1
(en)
*
|
1997-08-26 |
1999-03-04 |
Genentech, Inc. |
Rtd receptor
|
US20030175856A1
(en)
*
|
1997-08-26 |
2003-09-18 |
Genetech, Inc. |
Rtd receptor
|
US20060141036A1
(en)
*
|
1997-12-12 |
2006-06-29 |
Andrx Labs Llc |
HMG-CoA reductase inhibitor extended release formulation
|
CA2318029C
(en)
|
1998-01-15 |
2009-05-19 |
Genentech, Inc. |
Apo-2 ligand
|
JP2002517223A
(ja)
*
|
1998-06-12 |
2002-06-18 |
ジェネンテック・インコーポレーテッド |
モノクローナル抗体、交叉反応性抗体およびそれを生成する方法
|
US6984719B1
(en)
|
1998-09-17 |
2006-01-10 |
Hospital Sainte-Justine |
Peptide antagonists of prostaglandin F2α receptor
|
US6368793B1
(en)
|
1998-10-14 |
2002-04-09 |
Microgenomics, Inc. |
Metabolic selection methods
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
AU773891C
(en)
*
|
1998-10-23 |
2005-02-17 |
Kirin-Amgen Inc. |
Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
|
US6982153B1
(en)
|
1998-12-03 |
2006-01-03 |
Targanta Therapeutics, Inc. |
DNA sequences from staphylococcus aureus bacteriophage 77 that encode anti-microbial polypeptides
|
US6861442B1
(en)
|
1998-12-30 |
2005-03-01 |
Sugen, Inc. |
PYK2 and inflammation
|
CN1370238A
(zh)
|
1999-06-16 |
2002-09-18 |
艾科斯有限公司 |
人聚(adp-核酸)聚合酶2的物质和方法
|
US20040235749A1
(en)
*
|
1999-09-15 |
2004-11-25 |
Sylvain Chemtob |
G-protein coupled receptor antagonists
|
US20030138771A1
(en)
*
|
1999-09-30 |
2003-07-24 |
Jerry Pelletier |
DNA sequences from S. pneumoniae bacteriophage DP1 that encode anti-microbal polypeptides
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
KR100749982B1
(ko)
|
1999-11-16 |
2007-08-16 |
제넨테크, 인크. |
혈관 내피 성장 인자용 elisa
|
DE60117781T2
(de)
|
2000-04-21 |
2006-11-23 |
Amgen Inc., Thousand Oaks |
Peptidderivate des apolipoproteins-a1/aii
|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
EP1309373A2
(en)
*
|
2000-08-11 |
2003-05-14 |
Favrille, Inc. |
Method and composition for altering a t cell mediated pathology
|
US6911204B2
(en)
*
|
2000-08-11 |
2005-06-28 |
Favrille, Inc. |
Method and composition for altering a B cell mediated pathology
|
DK1385882T3
(da)
|
2001-05-11 |
2008-02-11 |
Amgen Inc |
Peptider og relaterede molekyler, der binder til TALL-1
|
IL161251A0
(en)
|
2001-10-10 |
2004-09-27 |
Neose Technologies Inc |
Remodeling and glycoconjugation of peptides
|
DK2279753T3
(en)
|
2001-10-10 |
2015-11-23 |
Novo Nordisk As |
The conversion of peptides and glycokonjugering
|
US7332474B2
(en)
*
|
2001-10-11 |
2008-02-19 |
Amgen Inc. |
Peptides and related compounds having thrombopoietic activity
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US20040054082A1
(en)
*
|
2001-12-03 |
2004-03-18 |
Bank David H |
Toughened polymer blends with improved surface properties
|
US20070122406A1
(en)
|
2005-07-08 |
2007-05-31 |
Xencor, Inc. |
Optimized proteins that target Ep-CAM
|
US20100311954A1
(en)
*
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
US7153829B2
(en)
*
|
2002-06-07 |
2006-12-26 |
Dyax Corp. |
Kallikrein-inhibitor therapies
|
WO2003103475A2
(en)
|
2002-06-07 |
2003-12-18 |
Dyax Corp. |
Prevention and reduction of blood loss
|
US7521530B2
(en)
|
2002-06-11 |
2009-04-21 |
Universite De Montreal |
Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
|
SI2386310T1
(sl)
*
|
2002-08-28 |
2019-03-29 |
Dyax Corp. |
Metode za ohranjanje organov in tkiv
|
US6919426B2
(en)
|
2002-09-19 |
2005-07-19 |
Amgen Inc. |
Peptides and related molecules that modulate nerve growth factor activity
|
MXPA05010773A
(es)
|
2003-04-09 |
2005-12-12 |
Neose Technologies Inc |
Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
|
WO2005016348A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Icos Corporation |
Method of inhibiting immune responses stimulated by an endogenous factor
|
WO2005016349A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Icos Corporation |
Methods of inhibiting leukocyte accumulation
|
US8883147B2
(en)
|
2004-10-21 |
2014-11-11 |
Xencor, Inc. |
Immunoglobulins insertions, deletions, and substitutions
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
US20060134105A1
(en)
*
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
US20050113458A1
(en)
*
|
2003-10-22 |
2005-05-26 |
Forest Laboratories, Inc. |
Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies
|
DE602005027673D1
(de)
|
2004-03-05 |
2011-06-09 |
Vegenics Pty Ltd |
Materialien und verfahren für wachstumsfaktorbindende konstrukte
|
CA2563334A1
(en)
*
|
2004-04-16 |
2005-11-17 |
Genentech, Inc. |
Assay for antibodies
|
LT2612862T
(lt)
|
2004-05-13 |
2017-01-25 |
Icos Corporation |
Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
|
EP1769243A2
(en)
*
|
2004-05-15 |
2007-04-04 |
Genentech, Inc. |
Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
|
CA2567883A1
(en)
*
|
2004-05-25 |
2005-12-15 |
Icos Corporation |
Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
|
MX2007000216A
(es)
*
|
2004-07-08 |
2007-03-15 |
Amgen Inc |
Peptidos terapeuticos.
|
EA011879B1
(ru)
|
2004-09-24 |
2009-06-30 |
Эмджин Инк. |
МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
|
US7235530B2
(en)
*
|
2004-09-27 |
2007-06-26 |
Dyax Corporation |
Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
|
CN102746404B
(zh)
|
2004-11-12 |
2016-01-20 |
赞科股份有限公司 |
对FcRn的结合被改变的Fc变体
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
CA2592390A1
(en)
|
2004-12-22 |
2006-06-29 |
Genentech, Inc. |
Methods for producing soluble multi-membrane-spanning proteins
|
CA2598409A1
(en)
*
|
2005-02-17 |
2006-08-24 |
Icos Corporation |
Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
WO2007056411A2
(en)
*
|
2005-11-08 |
2007-05-18 |
Genentech, Inc. |
Method of producing pan-specific antibodies
|
AR056806A1
(es)
|
2005-11-14 |
2007-10-24 |
Amgen Inc |
Moleculas quimericas de anticuerpo rankl- pth/ pthrp
|
US7276480B1
(en)
|
2005-12-30 |
2007-10-02 |
Dyax Corp. |
Prevention and reduction of blood loss
|
WO2007102946A2
(en)
|
2006-01-23 |
2007-09-13 |
Amgen Inc. |
Crystalline polypeptides
|
CA2643693A1
(en)
*
|
2006-03-10 |
2007-09-20 |
Dyax Corp. |
Formulations for ecallantide
|
US9283260B2
(en)
*
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
US7981425B2
(en)
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
ATE540681T1
(de)
|
2006-06-26 |
2012-01-15 |
Amgen Inc |
Verfahren zur behandlung von atherosklerose
|
JP5502480B2
(ja)
|
2006-09-18 |
2014-05-28 |
コンピュゲン エルティーディー. |
生物活性ペプチド及びその使用方法
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
TWI541251B
(zh)
|
2006-10-04 |
2016-07-11 |
建南德克公司 |
用於vegf之elisa
|
WO2008051383A2
(en)
*
|
2006-10-19 |
2008-05-02 |
Amgen Inc. |
Use of alcohol co-solvents to improve pegylation reaction yields
|
US8043829B2
(en)
*
|
2006-10-25 |
2011-10-25 |
Amgen Inc. |
DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
|
WO2008079322A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Beckman Coulter, Inc. |
Methods, kits and materials for diagnosing disease states by measuring isoforms or proforms of myeloperoxidase
|
AU2008262490B2
(en)
*
|
2007-05-22 |
2011-11-17 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
US8492329B2
(en)
|
2007-07-12 |
2013-07-23 |
Compugen Ltd. |
Bioactive peptides and methods of using same
|
JP5643643B2
(ja)
|
2007-07-26 |
2014-12-17 |
アムジエン・インコーポレーテツド |
変性レシチン−コレステロールアシルトランスフェラーゼ酵素
|
EP2201024A1
(en)
|
2007-08-28 |
2010-06-30 |
Ramot At Tel Aviv University |
Peptides inducing a cd4i conformation in hiv gp120 while retaining vacant cd4 binding site
|
PL2235059T3
(pl)
|
2007-12-26 |
2015-08-31 |
Xencor Inc |
Warianty FC o zmodyfikowanym wiązaniu do FCRN
|
US8129341B2
(en)
*
|
2008-08-25 |
2012-03-06 |
New York University |
Methods for treating diabetic wounds
|
KR20170060179A
(ko)
|
2008-11-13 |
2017-05-31 |
길리아드 칼리스토가 엘엘씨 |
혈액 종양에 대한 요법
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
CN102307594A
(zh)
*
|
2009-01-06 |
2012-01-04 |
戴埃克斯有限公司 |
用激肽释放酶抑制剂治疗粘膜炎
|
KR20120002995A
(ko)
|
2009-03-24 |
2012-01-09 |
길리아드 칼리스토가 엘엘씨 |
2―퓨리닐―3―톨릴―퀴나졸리논 유도체의 회전장애 이성질체 및 사용 방법
|
SG175259A1
(en)
*
|
2009-04-20 |
2011-11-28 |
Gilead Calistoga Llc |
Methods of treatment for solid tumors
|
KR20120049281A
(ko)
|
2009-07-21 |
2012-05-16 |
길리아드 칼리스토가 엘엘씨 |
Pi3k 억제제를 이용한 간 장애의 치료
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
EP2494356B1
(en)
*
|
2009-10-26 |
2017-03-15 |
Genentech, Inc. |
Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
|
AP2012006294A0
(en)
|
2009-11-05 |
2012-06-30 |
Rhizen Pharmaceuticals Sa |
Novel kinase modulators.
|
HUE039605T2
(hu)
|
2010-01-06 |
2019-01-28 |
Dyax Corp |
Plazma kallikreint kötõ proteinek
|
US20110189178A1
(en)
*
|
2010-02-04 |
2011-08-04 |
Xencor, Inc. |
Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
|
WO2011097527A2
(en)
|
2010-02-04 |
2011-08-11 |
Xencor, Inc. |
Immunoprotection of therapeutic moieties using enhanced fc regions
|
EP2547359B1
(en)
|
2010-03-15 |
2016-03-09 |
The Board of Trustees of the University of Illionis |
Inhibitors of beta integrin-g protein alpha subunit binding interactions
|
CA2798080C
(en)
|
2010-05-17 |
2020-08-25 |
Incozen Therapeutics Pvt. Ltd. |
3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
|
EP4056193A1
(en)
|
2010-06-17 |
2022-09-14 |
New York University |
Therapeutic and cosmetic uses and applications of calreticulin
|
WO2012030738A2
(en)
|
2010-08-30 |
2012-03-08 |
Beckman Coulter, Inc. |
Complex phosphoprotein activation profiles
|
EP3219731A1
(en)
|
2010-10-01 |
2017-09-20 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
WO2012087943A2
(en)
|
2010-12-20 |
2012-06-28 |
The Regents Of The University Of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
KR102320178B1
(ko)
|
2011-01-06 |
2021-11-02 |
다케다 파머수티컬 컴패니 리미티드 |
혈장 칼리크레인 결합 단백질
|
CA2830065A1
(en)
|
2011-03-16 |
2012-09-20 |
Amgen Inc. |
Potent and selective inhibitors of nav1.3 and nav1.7
|
WO2012149320A1
(en)
|
2011-04-29 |
2012-11-01 |
Bristol-Myers Squibb Company |
Ip-10 antibody dosage escalation regimens
|
EP2705029B1
(en)
|
2011-05-04 |
2018-10-24 |
Rhizen Pharmaceuticals S.A. |
Novel compounds as modulators of protein kinases
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
MY173865A
(en)
|
2011-09-22 |
2020-02-25 |
Amgen Inc |
Cd27l antigen binding proteins
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
KR20140133590A
(ko)
|
2012-03-05 |
2014-11-19 |
길리아드 칼리스토가 엘엘씨 |
(s)-2-(1-(9h-퓨린-6-일아미노)프로필)-5-플루오로-3-페닐퀴나졸린-4(3h)-온의 다형체 형태
|
WO2013142796A2
(en)
|
2012-03-23 |
2013-09-26 |
Bristol-Myers Squibb Company |
Methods of treatments using ctla4 antibodies
|
EP2831119A1
(en)
*
|
2012-03-28 |
2015-02-04 |
F. Hoffmann-La Roche AG |
Anti-hcmv idiotypic antibodies and uses thereof
|
EA026412B1
(ru)
|
2012-03-30 |
2017-04-28 |
Ризен Фармасьютикалз Са |
НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ c-MET ПРОТЕИНКИНАЗ
|
US10385395B2
(en)
|
2012-04-11 |
2019-08-20 |
The Regents Of The University Of California |
Diagnostic tools for response to 6-thiopurine therapy
|
AR091069A1
(es)
|
2012-05-18 |
2014-12-30 |
Amgen Inc |
Proteinas de union a antigeno dirigidas contra el receptor st2
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
EP3907237A1
(en)
|
2012-12-20 |
2021-11-10 |
Amgen Inc. |
Apj receptor agonists and uses thereof
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
EP2954332A1
(en)
|
2013-02-06 |
2015-12-16 |
Pieris AG |
Novel lipocalin-mutein assays for measuring hepcidin concentration
|
RS60026B1
(sr)
|
2013-02-18 |
2020-04-30 |
Vegenics Pty Ltd |
Molekuli koji vezuju ligande i njihove upotrebe
|
US9701743B2
(en)
|
2014-02-20 |
2017-07-11 |
Allergan, Inc. |
Complement component C5 antibodies
|
US10344060B2
(en)
|
2013-03-12 |
2019-07-09 |
Amgen Inc. |
Potent and selective inhibitors of Nav1.7
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
US9260527B2
(en)
|
2013-03-15 |
2016-02-16 |
Sdix, Llc |
Anti-human CXCR4 antibodies and methods of making same
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
TW201525001A
(zh)
|
2013-03-15 |
2015-07-01 |
Amgen Res Munich Gmbh |
包含n-端abp之單鏈結合分子
|
KR102588702B1
(ko)
|
2013-03-15 |
2023-10-16 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
|
JP6594855B2
(ja)
|
2013-03-15 |
2019-10-23 |
ゼンコア インコーポレイテッド |
ヘテロ二量体タンパク質
|
AU2014232416B2
(en)
|
2013-03-15 |
2017-09-28 |
Xencor, Inc. |
Modulation of T Cells with Bispecific Antibodies and FC Fusions
|
ES2973474T3
(es)
|
2013-05-30 |
2024-06-20 |
Kiniksa Pharmaceuticals Ltd |
Proteínas de enlace a antígeno del receptor de oncostatina M
|
US20160216262A1
(en)
|
2013-09-12 |
2016-07-28 |
Institut National De La Sante Et De La Recherche Medicale |
Method for In Vitro Quantifying Allo-Antibodies, Auto-Antibodies and/or Therapeutic Antibodies
|
BR112016004437A2
(pt)
|
2013-09-13 |
2017-10-17 |
Genentech Inc |
métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
|
AR097648A1
(es)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
|
SG10201802525QA
(en)
|
2013-09-13 |
2018-04-27 |
Genentech Inc |
Methods and compositions comprising purified recombinant polypeptides
|
EA036927B1
(ru)
|
2013-10-11 |
2021-01-15 |
Оксфорд Биотерепьютикс Лтд |
Конъюгированные антитела против ly75 для лечения рака
|
EP3083623A1
(en)
|
2013-12-20 |
2016-10-26 |
Gilead Calistoga LLC |
Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
|
EP3594215A1
(en)
|
2013-12-20 |
2020-01-15 |
Gilead Calistoga LLC |
Intermediate products in process methods for the preparation of phosphatidylinositol 3-kinase inhibitors
|
DK3094976T3
(da)
|
2014-01-17 |
2020-06-22 |
Minomic Int Ltd |
Celleoverfladeprostatakræftantigen til diagnose
|
WO2015130826A1
(en)
|
2014-02-27 |
2015-09-03 |
Allergan, Inc. |
COMPLEMENT FACTOR Bb ANTIBODIES
|
WO2015148790A1
(en)
|
2014-03-27 |
2015-10-01 |
Dyax Corp. |
Compositions and methods for treatment of diabetic macular edema
|
CN111410691B
(zh)
|
2014-03-28 |
2024-02-13 |
Xencor公司 |
结合至cd38和cd3的双特异性抗体
|
ES2950789T3
(es)
|
2014-06-10 |
2023-10-13 |
Amgen Inc |
Polipéptidos de apelina
|
EP3154960A1
(en)
|
2014-06-13 |
2017-04-19 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
CA2952540C
(en)
|
2014-07-31 |
2022-06-21 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibody construct with enhanced tissue distribution
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
JP6749312B2
(ja)
|
2014-07-31 |
2020-09-02 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH |
最適化された種間特異的二重特異性単鎖抗体コンストラクト
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
AR103852A1
(es)
|
2015-03-06 |
2017-06-07 |
Genentech Inc |
DsbA Y DsbC ULTRAPURIFICADOS Y SUS MÉTODOS DE PREPARACIÓN Y USO
|
WO2016149537A1
(en)
|
2015-03-17 |
2016-09-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bank vole prion protein as a broad-spectrum substrate for rt-quic-based detection and discrimination of prion strains
|
US10851144B2
(en)
|
2015-04-10 |
2020-12-01 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
KR20180023892A
(ko)
|
2015-04-17 |
2018-03-07 |
암젠 리서치 (뮌헨) 게엠베하 |
Cdh3 및 cd3에 대한 이중 특이성 항체 작제물
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
CN108026180B
(zh)
|
2015-08-28 |
2022-06-07 |
豪夫迈·罗氏有限公司 |
抗羟腐胺赖氨酸抗体及其用途
|
NZ744233A
(en)
|
2015-12-11 |
2023-11-24 |
Takeda Pharmaceuticals Co |
Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
|
JOP20170017B1
(ar)
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
|
US10781264B2
(en)
|
2016-02-03 |
2020-09-22 |
Amgen Research (Munich) Gmbh |
PSMA and CD3 bispecific T cell engaging antibody constructs
|
CR20180420A
(es)
|
2016-02-03 |
2018-12-05 |
Amgen Inc |
Constructos de anticuerpo biespecíficos para bcma y cd3 que se ligan a células t
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
JP7422480B2
(ja)
|
2016-05-04 |
2024-01-26 |
アムジエン・インコーポレーテツド |
制御性t細胞の増殖のためのインターロイキン-2変異タンパク質
|
WO2017200981A1
(en)
|
2016-05-16 |
2017-11-23 |
Baxalta Incorporated |
Anti-factor ix padua antibodies
|
CN117330747A
(zh)
|
2016-07-15 |
2024-01-02 |
武田药品工业株式会社 |
用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
|
CA3050009A1
(en)
|
2017-01-18 |
2018-07-26 |
Genentech, Inc. |
Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
US11918650B2
(en)
|
2017-05-05 |
2024-03-05 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
AU2018347521A1
(en)
|
2017-10-12 |
2020-05-07 |
Immunowake Inc. |
VEGFR-antibody light chain fusion protein
|
SG11202004273YA
(en)
|
2017-12-11 |
2020-06-29 |
Amgen Inc |
Continuous manufacturing process for bispecific antibody products
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
AR114437A1
(es)
|
2018-04-30 |
2020-09-02 |
Medimmune Ltd |
Conjugados para el direccionamiento hacia agregados y para la eliminación de los mismos
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
BR112020026724A2
(pt)
|
2018-07-02 |
2021-03-30 |
Amgen Inc. |
Proteína de ligação ao antígeno anti-steap1
|
US20210301017A1
(en)
|
2018-07-30 |
2021-09-30 |
Amgen Research (Munich) Gmbh |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
|
SG11202103275YA
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc |
Downstream processing of bispecific antibody constructs
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
MX2021014644A
(es)
|
2019-06-13 |
2022-04-06 |
Amgen Inc |
Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
|
CR20220111A
(es)
|
2019-08-13 |
2022-05-04 |
Amgen Inc |
Muteínas de interleucina-2 para la expansión de células t reguladoras referencia cruzada a solicitudes relacionadas
|
MX2022002981A
(es)
|
2019-09-10 |
2022-04-06 |
Amgen Inc |
Metodo de purificacion para polipeptidos de union a antigeno biespecificos con capacidad de union dinamica de captura de proteina l mejorada.
|
WO2021097344A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
BR112022011949A2
(pt)
|
2019-12-17 |
2022-11-22 |
Amgen Inc |
Dupla de interleucina-2/agonista do receptor tnf para uso em terapia
|
WO2021222333A1
(en)
|
2020-04-30 |
2021-11-04 |
Genentech, Inc. |
Kras specific antibodies and uses thereof
|
AU2021275049A1
(en)
|
2020-05-19 |
2022-12-22 |
Amgen Inc. |
MAGEB2 binding constructs
|
WO2021243320A2
(en)
|
2020-05-29 |
2021-12-02 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3
|
BR112022024472A2
(pt)
|
2020-06-01 |
2022-12-27 |
Genentech Inc |
Métodos para produzir um anticorpo, para detectar um anticorpo em uma amostra, para classificar células produtoras de anticorpos e para produzir uma pluralidade de vesículas, métodos de produção de um anticorpo e de tratamento de um indivíduo com uma doença, anticorpos isolados, ácido nucleico isolado, célula hospedeira, composição farmacêutica, uso do anticorpo isolado e kit
|
JP2023532266A
(ja)
|
2020-06-23 |
2023-07-27 |
ジアンスー カニョン ファーマシューティカル カンパニー リミテッド |
抗cd38抗体及びその使用
|
KR20230037560A
(ko)
|
2020-07-14 |
2023-03-16 |
에프. 호프만-라 로슈 아게 |
고정 용량 조합에 대한 분석
|
UY39508A
(es)
|
2020-11-06 |
2022-05-31 |
Amgen Res Munich Gmbh |
Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
|
MX2023011690A
(es)
|
2021-04-02 |
2023-12-15 |
Amgen Inc |
Construcciones de unión a mageb2.
|
EP4334358A1
(en)
|
2021-05-06 |
2024-03-13 |
Amgen Research (Munich) GmbH |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
CN113372514B
(zh)
*
|
2021-06-22 |
2022-06-14 |
安徽农业大学 |
一种刀豆蛋白聚合物水凝胶的制备方法、制得的水凝胶及其应用
|
WO2023218027A1
(en)
|
2022-05-12 |
2023-11-16 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
TW202421650A
(zh)
|
2022-09-14 |
2024-06-01 |
美商安進公司 |
雙特異性分子穩定組成物
|